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Oncogene-induced senescence is characterized by
a stable cell growth arrest, thus providing a tumor
suppression mechanism. However, the underlying
mechanisms for this phenomenon remain unknown.
Here,weshow that adecrease indeoxyribonucleotide
triphosphate (dNTP) levels underlies oncogene-
induced stable senescence-associated cell growth
arrest. The decrease in dNTP levels is caused by
oncogene-induced repression of ribonucleotide
reductase subunit M2 (RRM2), a rate-limiting protein
in dNTP synthesis. This precedes the senescence-
associated cell-cycle exit and coincides with the
DNA damage response. Consistently, RRM2 down-
regulation is both necessary and sufficient for senes-
cence. Strikingly, suppression of nucleotide meta-
bolism by RRM2 repression is also necessary for
maintenance of the stable senescence-associated
cell growth arrest. Furthermore, RRM2 repression
correlates with senescence status in benign nevi and
melanoma, and its knockdown drives senescence of
melanoma cells. These data reveal the molecular
basis whereby the stable growth arrest of oncogene-
induced senescence is established and maintained
through suppression of nucleotide metabolism.INTRODUCTION
Cellular senescence is defined as a state of stable cell growth
arrest (Campisi, 2005). Activation of oncogenes, such as RAS,
in normal mammalian cells typically triggers oncogene-induced
senescence (OIS) (Yaswen and Campisi, 2007), which is a
bona fide tumor suppressor mechanism in vivo (Campisi and1252 Cell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authorsd’Adda di Fagagna, 2007). For example, benign nevi formed by
human melanocytes that have undergone OIS are thought to
suppress melanomagenesis (Mooi and Peeper, 2006). Although
known to be important for tumor suppression, to date, the mo-
lecular mechanism underlying the stable OIS-associated cell
growth arrest remains unknown.
Oncogenic signaling triggers cellular senescence via various
senescence effectors. In particular, senescence induced by acti-
vated oncogenes such as RAS is characterized by a sustained
DNA damage response (DDR) triggered by aberrant DNA repli-
cation during the S phase of the cell cycle (Bartkova et al.,
2006; Di Micco et al., 2006). This ultimately activates the p53/
p21 and p16/pRB pathways (Serrano et al., 1997). Activation of
these signaling pathways cultivates the expression of markers
of senescence such as senescence-associated heterochromat-
in foci (SAHF), which are specialized domains of facultative het-
erochromatin that contribute to senescence by silencing prolifer-
ation-promoting genes (Narita et al., 2003; Zhang et al., 2007a),
and increased senescence-associated b-galactosidase (SA-
b-gal) activity (Dimri et al., 1995).
Cellular deoxyribonucleotide triphosphate (dNTP) levels play a
key role in regulating DNA replication and, consequently, cell
proliferation (Reichard, 1988). However, whether changes in
the nucleotide metabolic pathway play a role in regulating
OIS-associated stable cell growth arrest has never been investi-
gated. Ribonucleotide reductase (RNR) plays a key role in dNTP
biogenesis (Nordlund and Reichard, 2006). RNR is a tetrameric
complex consisting of two large catalytic subunits (termed
RRM1) and two small regulatory subunits (RRM2 or p53R2) (Nor-
dlund and Reichard, 2006). Notably, RRM2 is the regulatory sub-
unit that controls dNTP synthesis during the S phase of the cell
cycle, whereas RRM1 is present throughout the cell cycle (Eng-
stro¨m et al., 1985). Importantly, RRM2 expression is rate-limiting
for RNR activity (Nordlund and Reichard, 2006). In contrast,
p53R2 is involved in supplying dNTPs for DNA repair and mito-
chondrial DNA synthesis in the G0/G1 phase of the cell cycle
(Ha˚kansson et al., 2006). Whether RRM2 plays a role in
regulating OIS, which is characterized by aberrant DNA replica-
tion, the DDR, and a stable cell growth arrest, has never been
investigated.
Here, we report that a decrease in dNTP levels underlies the
establishment and maintenance of the stable OIS-associated
cell growth arrest. We show that addition of exogenous nucleo-
sides is sufficient to overcome OIS-associated cell growth
arrest, which correlates with suppressing aberrant DNA replica-
tion and inhibiting the DDR. Mechanistically, we discovered that
the decrease in dNTP levels is caused by oncogene-induced
suppression of RRM2 expression. This correlates with the
recruitment of E2F7, an atypical E2F transcriptional repressor,
to its promoter. Indeed, we show that RRM2 downregulation
is both necessary and sufficient for the establishment and main-
tenance of the stable senescence-associated cell growth arrest.
Further underscoring the importance of this pathway in regu-
lating senescence in human cancers, we show that RRM2
expression inversely correlates with senescence status in human
nevi and melanoma specimens harboring oncogenic BRAF
or NRAS. Additionally, high RRM2 expression correlates with
poor overall survival in patients with melanoma with oncogenic
BRAF or NRAS. Finally, knockdown of RRM2 drives senescence
of melanoma cells harboring these activated oncogenes. Taken
together, our results reveal the mechanistic basis whereby an
activated oncogene establishes and maintains the stable senes-
cence-associated cell growth arrest by suppressing nucleotide
metabolism.
RESULTS
Exogenous Nucleosides Suppress OIS and Its
Associated Cell Growth Arrest
Senescent cells are characterized by a stable cell growth arrest
(Campisi, 2005), and nucleotide metabolism plays a critical role
in regulating cell growth (Reichard, 1988). To test the hypothesis
that nucleotide metabolism regulates OIS, IMR90 primary
human fibroblasts were infected with RAS-encoding retrovirus
to induce senescence (Figure S1A), and exogenous nucleosides
were added at the time of infection. Compared with controls,
addition of exogenous nucleosides significantly suppressed
the expression of markers of senescence such as SAHF forma-
tion (Figures 1A and 1B), SA-b-gal activity (Figures 1A and 1B),
and the upregulation of p16, p21, and p53 (Figure 1C). In addi-
tion, senescence induced by oncogenic RAS is characterized
by the DDR (Bartkova et al., 2006; Di Micco et al., 2006). Thus,
we examined markers of the DDR such as formation of gH2AX
foci in these cells. Compared with controls, addition of exoge-
nous nucleosides significantly decreased gH2AX foci formation
(Figures 1D and 1E). Next, we determined the effects of exoge-
nous nucleosides on the senescence-associated cell-cycle exit
by bromodeoxyuridine (BrdU) incorporation. Exogenous nucleo-
sides significantly increased BrdU incorporation in RAS-infected
cells compared with controls (Figures 1F and 1G). Finally, we
sought to determine the effects of exogenous nucleosides on
the OIS-associated cell growth arrest by colony-formation and
cell growth curve assays. Compared with RAS-alone controls,
there was a significant increase in colony formation (Figure 1H)
and cell growth (Figure 1I) in exogenous nucleoside-supple-Cmented cells. Interestingly, senescence induced by DNA dam-
age reagents such as doxorubicin or etoposide was not affected
by addition of exogenous nucleosides (Figures S1B–S1I), sug-
gesting that the observed effects are not merely a consequence
of DNA damage. Based on these results, we conclude that exog-
enous nucleosides added at the time of infection are sufficient to
suppress OIS and its associated cell growth arrest.
Exogenous Nucleosides Are Sufficient to Overcome
the OIS-Associated Cell Growth Arrest in Established
Senescent Cells
We next wanted to determine the effects of exogenous nucleo-
sides on the stable OIS-associated cell growth arrest in estab-
lished senescent cells. To do so, stable senescence-associated
cell growth arrest was established by culturing RAS-infected
cells for 6 days, as evidenced by the minimal BrdU incorporation
in these cells compared with controls as well as no appreciable
cell growth during the experimental period (Figures S2A–S2C).
Then FACSwas performedwith C12FDG, a fluorogenic substrate
for SA-b-gal activity in live cells (Debacq-Chainiaux et al., 2009)
(Figure 2A). FACS-sorted senescent cells were further cultured
with or without exogenous nucleosides. We then examined the
expression of markers of senescence and proliferation in these
cells. Compared with controls, markers of senescence such as
SA-b-gal activity and p16 and p21 expression were all sup-
pressed by exogenous nucleosides (Figures 2B–2D). In contrast,
markers of cell proliferation, such as BrdU incorporation, were
increased in the established senescent cells exposed to exoge-
nous nucleosides (Figure 2E). Strikingly, addition of exogenous
nucleosides to these cells reversed the oncogene-induced sta-
ble senescence-associated cell growth arrest, as evidenced by
marked growth of these cells (Figure 2F). Notably, these obser-
vations were not due to a loss of RAS expression because
RAS was expressed at similar levels in these cells compared to
those without exposure to exogenous nucleosides (Figure S2D).
Similar observations were also made when RAS cells were al-
lowed to senescence for a longer period of time (e.g., exogenous
nucleosides added at day 12; Figures S2E–S2G). Likewise, we
also observed similar effects of exogenous nucleosides in
another primary human fibroblast cell line, WI38 (Figures S2H–
S2J), demonstrating that this is not a cell line-specific phenom-
enon. Interestingly, withdrawal of nucleosides from these cells
was sufficient for the cells to senesce again, as shown by an in-
crease in SA-b-gal activity (Figures 2G and 2H) and p21 and p16
expression (Figure 2I), and a decrease in both cyclin A expres-
sion (Figure 2I) and cell growth (Figure 2J). Taken together, these
data indicate that addition of exogenous nucleosides is sufficient
to overcome the stable OIS-associated cell growth arrest in es-
tablished senescent cells.
A Decrease in dNTP Levels Occurs Prior
to the OIS-Associated Cell-Cycle Exit
Because addition of exogenous nucleosides suppresses senes-
cence (Figures 1 and 2), we next sought to determine whether
changes in dNTP levels occur during OIS. Toward this goal, we
measured dNTP levels in control and RAS-infected IMR90 cells.
To limit the potential effects of cell cycle and cell proliferation
status on dNTP levels, we performed a detailed time courseell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authors 1253
Figure 1. Exogenous Nucleosides Suppress OIS and Its Associated Cell Growth Arrest
(A) IMR90 cells were infected with control or RAS-encoding retrovirus with or without addition of the indicated concentration of nucleosides (NS) at the time of
infection. On day 6, drug-selected cells were examined for SAHF formation and SA-b-gal activity.
(B) Quantification of (A). Mean of three independent experiments with SEM is shown. *p < 0.05.
(C) Same as (A) but examined for expression of RAS, p21, p16, p53, and b-actin by immunoblotting.
(D) Same as (A) but stained for gH2AX foci formation. DAPI counterstaining was used to visualize nuclei.
(E) Quantification of (D). Mean of three independent experiments with SEM is shown. *p < 0.05.
(F) Same as (A) but labeled with BrdU for 1 hr. The incorporated BrdU was visualized by immunofluorescence. DAPI counterstaining was used to visualize nuclei.
(G) Quantification of (F). Mean of three independent experiments with SEM is shown. *p < 0.01.
(H) Same as (A), but an equal number of cells were inoculated in 6-well plates. After 2 weeks, the plates were stained with 0.05% crystal violet in PBS to visualize
colony formation. Shown are representative images of three independent experiments.
(I) Same as (A), but an equal number of cells were seeded in 6-well plates. The number of cells was counted at the indicated time points after infection. Mean of
three independent experiments with SEM is shown. *p < 0.05 compared with RAS-alone cells.
See also Figure S1.analysis for cell-cycle distribution using FACS analysis, markers
of cell proliferation such as serine 10 phosphorylated histone H3
(pS10H3), andmarkers of senescence such as p21 and p16 (Fig-
ures S3A and S3B). Based on the time course analysis, we deter-
mined the dNTP levels on day 2, which is prior to the cell-cycle
exit, as further demonstrated by comparable BrdU incorporation
and cyclin A expression in RAS-infected cells compared to con-
trols (Figures S3C–S3E). Strikingly, the levels of all four dNTPs
were significantly decreased in RAS-infected cells compared
with controls at this time point (Figure 3A). Together, these
data support the idea that there is a decrease in dNTP levels,
which occurs prior to the OIS-associated cell-cycle exit.
Addition of exogenous nucleosides suppresses OIS-associ-
ated DDR (Figures 1C–1E), which is triggered by aberrant DNA
replication (Bartkova et al., 2006; Di Micco et al., 2006). More-
over, RAS significantly decreases dNTP levels prior to the senes-
cence-associated cell-cycle exit (Figure 3A). Thus, we sought to
determine whether the decrease in dNTP levels plays a role in
regulating aberrant DNA replication induced by oncogenic
RAS. Toward this goal, we determined the changes in the1254 Cell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authorsdynamics of DNA replication in control and RAS-infected cells
with or without exogenous nucleosides using the DNA-combing
analysis (Figures S3F and S3G). This allows for observation of
single-stranded DNA (ssDNA) to determine DNA replication
fork dynamics (namely elongating, terminated, and newly fired,
as illustrated in Figure S3G). Indeed, addition of exogenous
nucleosides significantly rescued the aberrant DNA replication
observed during RAS-induced senescence (Figure 3B). Notably,
this correlates with a significant restoration of dNTP levels in
RAS-infected cells supplemented with exogenous nucleosides
(Figure 3C). This result is consistent with the idea that the
observed effects are due to restoration of dNTP levels. Together,
these results support the premise that a decrease in dNTP levels
contributes to the aberrant DNA replication observed during
RAS-induced senescence.
Oncogene-Induced Repression of RRM2 Occurs Prior
to the Senescence-Associated Cell-Cycle Exit
We next wanted to determine the molecular mechanism
whereby dNTP levels decrease during OIS. RNR is a key enzyme
Figure 2. Exogenous Nucleosides Are Sufficient to Overcome the Stable OIS-Associated Cell Growth Arrest in Established Senescent Cells
(A) IMR90 cells were infected with RAS-encoding retrovirus. On day 6, drug-selected cells were subjected to flow cytometric sorting (FACS) of SA-b-gal-positive
cells using C12FDG as a substrate. Black bar indicates the gate used for sorting.
(B) FACS-sorted senescent cells were cultured without or with indicated concentrations of nucleosides for an additional 14 days. The cells were then stained for
SA-b-gal activity.
(C) Quantification of (B). Mean of three independent experiments with SEM is shown. *p < 0.001.
(D) Same as (B) but examined for p16, p21, and b-actin expression by immunoblotting.
(E) Same as (B) but labeled with BrdU for 1 hr. Mean of three independent experiments with SEM is shown.
(F) Same as (B), but an equal number of cells that overcome senescence or control (parental) cells were inoculated in 6-well plates, and the number of cells was
counted at the indicated time points. Mean of three independent experiments with SEM is shown.
(G) Cells that overcome senescence in the presence of exogenous nucleosides (50 nM) isolated from (B) (rescued cells) were continually cultured in the presence
of NS (control) or withdrawn from NS exposure for an additional 17 days and stained for SA-b-gal activity.
(H) Quantification of (G). Mean of three independent experiments with SEM is shown. *p < 0.01.
(I) Same as (G) but examined for p21, p16, cyclin A, and b-actin expression by immunoblotting.
(J) Same as (G), but an equal number of cells were inoculated in 6-well plates after withdrawal, and the number of cells was counted 4 days later. Mean of three
independent experiments with SEM is shown. *p < 0.05.
See also Figure S2.in dNTP biosynthesis, and RRM2, the regulatory subunit of RNR,
is rate-limiting for this process (Nordlund and Reichard, 2006).
Thus, we sought to determine whether RRM2 expression is regu-
lated during OIS. To do so, we examined the protein levels of
RRM2 in control and RAS-infected cells in a detailed time course
study comparing the kinetics of RRM2 expression with the
expression of markers of cell proliferation such as cyclin A and
pS10H3. Strikingly, as early as day 1, when RAS cells are still
proliferating based on the expression of cyclin A and pS10H3
(Figures 4A and S3B), RRM2 protein expression was already
decreased in RAS-infected cells compared to controls (Fig-
ure 4A). At this time point, expression of other regulators of
dNTP metabolism, namely RRM1 and p53R2, was not
decreased (Figure S4A), demonstrating that this is specific to
RRM2. We next sought to determine the changes in RRM2
expression in cycling cells by staining for the RRM2 protein in
BrdU-positive cells (transiently labeled for 1 hr). The RRM2-Cstaining signal was specific because knockdown of RRM2
protein decreased the immunofluorescent signal (Figure S4B).
Indeed, RRM2 protein expression was decreased even in
BrdU-positive RAS-infected cells (Figure 4B). Notably, RRM2
downregulation coincided with the DDR as evidenced by the
accumulation of gH2AX (Figure 4A), suggesting that downregu-
lation of RRM2 may contribute to the DDR observed during
OIS. However, RRM2 downregulation was not a consequence
of the DDR because ionizing radiation, which induces DNA
damage, failed to suppress RRM2 expression (Figure S4C).
Together, these results indicate that RRM2 is downregulated
prior to the OIS-associated cell-cycle exit and coincides with
activation of the DDR during senescence.
We next sought to determine themolecular mechanism under-
lying downregulation of RRM2 during OIS. First, we asked
whether RRM2 is downregulated at the transcriptional level.
Accordingly, quantitative RT-PCR (qRT-PCR) was performed inell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authors 1255
Figure 3. A Decrease in dNTP Levels Occurs Prior to the OIS-
Associated Cell-Cycle Exit
(A) IMR90 cells were infected with control or RAS-encoding retrovirus. On day
2, cellular dNTP levels were measured. Mean of three independent experi-
ments with SEM is shown. *p < 0.05.
(B) Same as (A), but RAS-infected cells were supplemented with or without the
indicated concentration of nucleosides at the time of infection. Mean of three
independent experiments with SEM is shown. *p < 0.05 control versus RAS;
#p < 0.05 RAS versus RAS plus 50 or 250 nM NS.
(C) Same as (B), but cellular dNTP levels were measured. Mean of three
independent experiments with SEM is shown. *p < 0.05 versus control;
#p < 0.05 versus RAS alone.
See also Figure S3.control and RAS-infected cells. Similar to RRM2 protein expres-
sion, RRM2mRNA expression was significantly decreased after
RAS infection but prior to the senescence-associated cell-cycle
exit (i.e., at day 1; Figure 4C). Consistent with the idea that
decreased RRM2 mRNA expression is due to decreased tran-1256 Cell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authorsscription, there was a significant decrease in the activity of the
cloned human RRM2 gene proximal promoter (1,071 to +76)
in the RAS-infected cells compared with controls (Figures 4D
and S4D). Together, we conclude that RRM2 is downregulated
at the transcriptional level, and this occurs before the senes-
cence-associated cell-cycle exit.
To identify the transcription factor that contributes to RRM2
repression during senescence, systematic promoter mapping
was performed. Notably, an E2F binding site within the proximal
promoter (998 to991) was identified to contribute to the sup-
pression of RRM2 transcription in response to RAS (Figure 4D;
data not shown). Deletion of the E2F binding site in the RRM2
promoter significantly restored promoter activity in RAS-infected
cells (Figure 4D). Chromatin immunoprecipitation (ChIP) experi-
ments using an E2F1 antibody demonstrated that the binding
of transcriptional activator E2F1 to the human RRM2 gene pro-
moter was significantly reduced in RAS-infected cells compared
with controls (Figure 4E). Interestingly, RRM2 is downregulated,
whereas the cells are highly proliferative, and other E2F1 target
genes such as cyclin A remain highly expressed (e.g., Figure 4A).
These results suggest that the RRM2 downregulation observed
during OIS is context dependent. To further determine themech-
anism of RRM2 downregulation, we performed ChIP analysis
using antibodies to the repressive E2F transcriptional factors
E2F4 and E2F7 (Chen et al., 2009). These data demonstrate
that binding of the atypical transcriptional repressor E2F7 to
the human RRM2 gene promoter was significantly enhanced in
RAS-infected cells compared to controls (Figure 4E), whereas
there was no change in E2F4 binding (data not shown). Indeed,
a detailed time course study revealed that downregulation of
RRM2 coincides with upregulation of E2F7 during RAS-induced
senescence (Figure 4F). These results indicate that an enhanced
association of the atypical transcriptional repressor E2F7 with
the RRM2 gene promoter and a simultaneous decrease in bind-
ing of transcriptional activator E2F1 to the RRM2 gene promoter
contribute to downregulation of RRM2 prior to the OIS-associ-
ated cell-cycle exit.
Knockdown of RRM2 Induces Senescence in Primary
Human Fibroblasts
We next wanted to determine whether RRM2 downregulation is
sufficient to induce senescence. To do so, we infected cells with
lentivirus encoding small hairpin RNAs to the human RRM2 gene
(shRRM2). The knockdown efficacy of shRRM2 was confirmed
by qRT-PCR and immunoblotting (Figures 5A and S5A). Consis-
tent with the hypothesis that RRM2 downregulation decreases
the dNTP levels observed during senescence, we determined
that knockdown of RRM2 caused a significant decrease in
dNTP levels (Figure S5B). In addition, we determined that knock-
down of RRM2 triggers aberrant DNA replication (Figures 5B
and S5C). Furthermore, DDR markers such as formation of
53BP1 and gH2AX foci were significantly induced by shRRM2
(Figures 5C, 5D, S5D, and S5E). Likewise, gH2AX and p53 pro-
tein expression was upregulated in shRRM2-expressing cells
compared to controls (Figures 5E and S5F). Together, these re-
sults support the idea that a decrease in dNTP levels caused by
RRM2 downregulation drives aberrant DNA replication and
consequently the DDR observed during OIS.
Figure 4. Oncogene-Induced Repression of RRM2 Occurs Prior to the OIS-Associated Cell-Cycle Exit
(A) IMR90 cells were infected with control or RAS-encoding retrovirus. The expression of RRM2, cyclin A, gH2AX, and b-actin was determined by immunoblotting
at the indicated time points after completing RAS infection.
(B) IMR90 cells were infected with control or RAS-encoding retrovirus. On day 1, the infected cells were labeled with BrdU for 1 hr, and the expression of RRM2 in
BrdU-incorporated cells was visualized by immunofluorescence.
(C) Same as (A), but cells were examined for RRM2 mRNA expression by qRT-PCR on day 1. Mean of three independent experiments with SEM is shown.
*p < 0.01.
(D) On day 2, drug-selected control or RAS-infected cells were electroporated with a luciferase reporter driven by aWT or E2F binding site-deleted (DE2F) mutant
human proximal RRM2 gene promoter. A luminescent b-gal reporter was used as an internal control to normalize the transfection efficacy. Mean of three in-
dependent experiments with SEM is shown. *p < 0.001 Control/WT versus RAS/WT; **p < 0.05 WT versus DE2F.
(E) Same as (C), but cells were examined for E2F1 and E2F7 binding to theRRM2 promoter by ChIP using an E2F1 or E2F7 antibody. An isotype-matched IgGwas
used as a control. Mean of three independent experiments with SEM is shown. *p < 0.001.
(F) IMR90 cells were infected with control or RAS-encoding retrovirus. Expression of RRM2, E2F1, and E2F7mRNAwas determined by qRT-PCR at the indicated
time points. Mean of three independent experiments with SEM is shown.
See also Figure S4.Wenext determined whether knockdown of RRM2 is sufficient
to induce senescence and the associated cell-cycle exit.
Compared with controls, markers of senescence such as SA-
b-gal activity (Figures 5F, 5G, S5G, and S5H) were induced by
RRM2 knockdown. Consistently, markers of cell proliferation,
including expression of cyclin A and pS10H3 (Figures 5H and
S5I) and BrdU incorporation (Figures 5I, 5J, S5J, and S5K),
were lower in shRRM2-expressing cells. Indeed, senescence-
associated cell growth arrest was evident in RRM2 knockdown
cells, as demonstrated by assays such as colony formation (Fig-
ures 5K and S5L) and cell growth curves (Figure 5L). Together,
we conclude that knockdown of RRM2 induces cellular senes-
cence in primary human fibroblasts.
To limit the potential off-target effects of shRNAs, we per-
formed rescue experiments by infecting cells with a retrovirus
encoding a wild-type (WT) RRM2 cDNA together with a lenti-
virus encoding an shRRM2 that targets the 50 UTR of the
human RRM2 gene. Knockdown of endogenous RRM2 was
confirmed by downregulation of RRM2 mRNA measured byCqRT-PCR using primers targeting the 50 UTR (Figure 5A),
whereas expression of ectopic RRM2 was confirmed by
expression of RRM2 mRNA measured by qRT-PCR using
primers targeting the open reading frame (ORF) region and
immunoblotting (Figures 5A and 5E). Indeed, compared with
cells expressing shRRM2 alone, ectopic RRM2 expression
rescued the aberrant DNA replication induced by shRRM2 (Fig-
ure 5B). Additionally, the DDR induced by shRRM2 was also
suppressed by ectopic RRM2. Formation of gH2AX and
53BP1 foci (Figures 5C and 5D) and gH2AX and p53 expression
(Figure 5E) were significantly lower in cells expressing both
shRRM2 and ectopic RRM2 compared with shRRM2 alone.
Furthermore, expression of markers of senescence such as
SA-b-gal activity (Figures 5F and 5G) and upregulation of p21
(Figure 5H) was inhibited by ectopic RRM2 in the shRRM2-ex-
pressing cells. Moreover, ectopic RRM2 was sufficient to
rescue the senescence-associated cell-cycle exit induced by
RRM2 knockdown, as demonstrated by upregulation of cyclin
A and pS10H3 (Figure 5H), increased BrdU incorporationell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authors 1257
Figure 5. Knockdown of RRM2 Decreases dNTP Levels and Induces Senescence of Primary Human Fibroblasts
(A) IMR90 cells were infected with a lentivirus-encoding shRRM2 that targets the 50 UTR of the humanRRM2 gene together with a retrovirus encoding a control or
WT RRM2. On day 6, expression of RRM2mRNA was determined by qRT-PCR using primers designed to its 50 UTR (only amplifies endogenous but not ectopic
RRM2 mRNA) or its ORF (amplifies both endogenous and ectopic RRM2 mRNA). Mean of three independent experiments with SEM is shown.
(B) Same as (A) but examined for DNA replication dynamics using the DNA-combing technique on day 2. Mean of three independent experiments with SEM is
shown. *p < 0.05 control versus shRRM2; #p < 0.05 shRRM2 alone versus shRRM2/RRM2.
(C) Same as (A) but examined for formation of 53BP1 and gH2AX foci by immunofluorescence at day 6.
(D) Quantification of (C). Mean of three independent experiments with SEM is shown. #p < 0.001 versus vector controls; *p < 0.001 versus shRRM2-only cells.
(E) Same as (A) but examined for RRM2, gH2AX, p53, and b-actin expression by immunoblotting.
(F) Same as (A) but stained for SA-b-gal activity.
(G) Quantification of (F). Mean of three independent experiments with SEM is shown. *p < 0.001.
(H) Same as (A) but examined for p21, cyclin A, pS10H3, and b-actin by immunoblotting.
(I) Same as (A) but labeled with BrdU for 1 hr, and the incorporated BrdU was visualized by immunofluorescence. DAPI counterstaining was used to visualize
nuclei.
(J) Quantification of (I). The relative percentage of BrdU-positive cells was calculated against vector controls. Mean of three independent experiments with SEM is
shown. *p < 0.001.
(K) Same as (A), but an equal number of the indicated cells were seeded in 6-well plates. After 2 weeks, the plates were stained with 0.05% crystal violet in PBS to
visualize colony formation. Shown are representative images from three independent experiments.
(L) Same as (K), but the number of cells was counted at the indicated time points. Mean of three independent experiments with SEM is shown. *p < 0.001
compared with cells expressing shRRM2 alone.
See also Figure S5.(Figures 5I and 5J), colony formation (Figure 5K), and cell
growth (Figure 5L) compared to shRRM2 alone. Notably, the
ectopically expressed RRM2 levels were comparable to its1258 Cell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authorsendogenous level (Figures 5A and 5E), suggesting that the
observed effects are not due to supraphysiological levels of
RRM2 expression. Together, we conclude that knockdown of
RRM2 is sufficient to trigger aberrant DNA replication, the DDR,
and senescence in primary human cells.
Ectopic RRM2 Expression Is Sufficient to Overcome the
Stable OIS-Associated Cell Growth Arrest
We next sought to determine whether downregulation of RRM2
is necessary for the OIS-associated cell growth arrest. Toward
this goal, we ectopically expressed RRM2 in RAS-infected
cells. Compared with controls, ectopic RRM2 suppressed
markers of senescence such as SA-b-gal activity and SAHF
formation (Figures 6A and 6B) and upregulation of p16 and
p21 (Figure 6C). Indeed, ectopic RRM2 suppressed the OIS-
associated cell-cycle exit, as evidenced by the significant in-
crease in cyclin A and pS10H3 expression (Figure 6C) and
BrdU incorporation (Figures 6D and 6E). Ectopic RRM2 signifi-
cantly suppressed the OIS-associated growth arrest as deter-
mined by colony-formation assays (Figure 6F) and cell growth
curves (Figure 6G). Of note, to limit the effects of supraphysio-
logical levels of RRM2 expression, we expressed the ectopic
RRM2 at a level lower than that of control cells (Figure 6C).
Importantly, the observed effects correlated with the rescue
of dNTP levels by ectopic RRM2 in these cells (Figure 6H),
further supporting the idea that RRM2 downregulation plays a
major role in decreasing dNTP levels during OIS. In addition,
ectopic RRM2 significantly suppressed the aberrant DNA repli-
cation observed during RAS-induced senescence (Figure 6I).
This result suggests that RRM2 suppresses aberrant DNA
replication by rescuing the decrease in dNTP levels. Likewise,
the DDR was also suppressed by ectopic RRM2, as demon-
strated by a decrease in the formation of 53BP1 and gH2AX
foci (Figures 6J and 6K) as well as a decrease in p53 and
gH2AX protein expression (Figure 6L). Based on these data,
we conclude that RRM2 downregulation is necessary for
senescence, and restoration of dNTP levels by ectopic RRM2
expression suppresses senescence.
We found that exogenous nucleosides are sufficient to
overcome the OIS-associated cell growth arrest in established
senescent cells (Figure 2). Because ectopic RRM2 is sufficient
to rescue the decrease in dNTP levels during senescence
(Figure 6H), we next sought to determine whether ectopic
RRM2 expression is sufficient to overcome the stable OIS-
associated cell growth arrest in established senescent cells.
To do so, stably arrested senescent cells induced by RAS
were infected with a lentivirus encoding RRM2 (which can
infect growth-arrested, nondividing cells), and markers of
senescence and cell cycle were examined. Compared with
controls, markers of senescence such as SA-b-gal activity
and p16 expression were suppressed by the lentivirus-
mediated RRM2 expression (Figures 6M–6O). Significantly,
expression of RRM2 was able to overcome the stable OIS-
associated arrest, as evidenced by both increased pS10H3
expression and marked cell growth (Figures 6O and 6P).
These observations were not due to a loss of RAS expression
because RAS was expressed at similar levels in both control
and RRM2-expressing cells (Figure 6O). Together, these data
indicate that RRM2 repression is necessary for maintenance
of the stable senescence-associated cell growth arrest in
established senescent cells.CRRM2Repression Correlateswith Senescence Status in
Human Nevi and Malignant Melanoma Harboring
Oncogenic BRAF or NRAS
We next sought to determine the importance of our findings in a
pathologically relevant model. Benign human nevi harboring
activated oncogenes are comprised of oncogene-induced
senescent melanocytes (Michaloglou et al., 2005). In addition,
there is evidence to suggest that the progression of benign
nevi with oncogenic BRAF or NRAS into malignant melanoma
correlates with OIS bypass (Dankort et al., 2007; Dhomen
et al., 2009; Kuilman et al., 2010). Thus, we sought to validate
our findings by examining RRM2 expression in human benign
nevi and malignant melanoma specimens. First, we determined
whether RRM2 is downregulated during oncogenic BRAF or
NRAS-induced senescence of primary human melanocytes.
Indeed, RRM2 expression was significantly inhibited during
senescence of melanocytes induced by oncogenic BRAF or
NRAS (Figures 7A–7C and S6A–S6C). Similar to what we
observed in primary human fibroblasts (Figure 1), exogenous
nucleosides were able to suppress senescence induced by
oncogenic BRAF in primary human melanocytes (Figures S6D–
S6F). These results suggest that RRM2 expression may promote
melanoma by suppressing oncogenic BRAF or NRAS-induced
senescence.
We also determined that RRM2 expression was significantly
increased in human melanoma cells harboring oncogenic
BRAF or NRAS compared to normal human melanocytes (Fig-
ure 7D). Notably, it has previously been demonstrated that
supraphysiological levels of RRM2 promote tumorigenesis by
causing genomic instability and the DDR (D’Angiolella et al.,
2012; Xu et al., 2008). Consistently, we observed that physiolog-
ical levels of RRM2 suppress oncogenic RAS-induced DDR (Fig-
ure 6), whereas DDR markers such as gH2AX remain high in
RAS-infected cells expressing supraphysiological levels of
RRM2 (Figures S6G and S6H).
We next compared expression of RRM2, the senescence
marker p16, and the cell proliferation marker Ki67 in a cohort
of human benign nevi and melanoma specimens harboring
oncogenic BRAF or NRAS (Table S1). Strikingly, RRM2 expres-
sion was nearly negative in human nevi with oncogenic BRAF
or NRAS, whereas the expression of RRM2 was significantly
higher in the melanoma specimens with oncogenic BRAF or
NRAS (Figures 7E and 7F). Consistently, expression of p16
was significantly higher in benign human nevi compared to
malignant melanomas (Figures 7E and S6I). In contrast, expres-
sion of Ki67 was negative in benign human nevi and significantly
higher in melanoma specimens (Figures 7E and S6J). These re-
sults are consistent with the idea that the supraphysiological
levels of RRM2 observed in melanoma specimens contribute
tomelanoma by suppressing oncogenic BRAF or NRAS-induced
senescence. We next determined whether RRM2 expression
negatively correlates with survival in patients with melanoma
harboring oncogenic BRAF or NRAS. Indeed, high RRM2
expression significantly correlates with poor overall survival in
these patients with melanoma (Figure 7G). In contrast, expres-
sion of RRM1 does not correlate with the survival of patients
with melanoma harboring oncogenic BRAF or NRAS (Fig-
ure S6K). We conclude that RRM2 repression correlates withell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authors 1259
Figure 6. Ectopic RRM2 Expression Suppresses Senescence and Is Sufficient to Overcome the Stable OIS-Associated Cell Growth Arrest
(A) IMR90 cells were coinfected with retrovirus-encoding control or RAS together with or without RRM2. Cells were examined for SA-b-gal activity or SAHF
expression on day 6.
(B) Quantification of (A). Mean of three independent experiments with SEM is shown. *p < 0.05 control versus RAS; #p < 0.05 RAS alone versus RAS/RRM2.
(C) Same as (A) but examined for RAS, RRM2, cyclin A, pS10H3, p21, p16, and b-actin expression by immunoblotting.
(D) Same as (A), but the cells were labeled with BrdU for 1 hr, and the BrdU incorporation was visualized by immunofluorescence. DAPI counterstaining was used
to visualize nuclei.
(E) Quantification of (D). Mean of three independent experiments with SEM is shown. *p < 0.01.
(F) Same as (A), but an equal number of the indicated cells were seeded in 6-well plates. After 2 weeks, the plates were stained with 0.05% crystal violet in PBS to
visualize colony formation. Shown are representative images from three independent experiments.
(G) Same as (F), but the number of cells was counted at the indicated time points. Mean of three independent experiments with SEM is shown. *p < 0.01.
(H) Same as (A), but on day 2, the concentrations of all four dNTPs were examined. p < 0.05 control versus RAS (*) and p < 0.05 RAS alone versus RAS/RRM2 (#).
Mean of three independent experiments with SEM is shown.
(I) Same as (H) but examined for DNA replication dynamics using the DNA-combing technique on day 2. Mean of three independent experiments with SEM is
shown. *p < 0.05 control versus RAS; #p < 0.05 RAS alone versus RAS/RRM2.
(J) Same as (A) but examined for the formation of 53BP1 and gH2AX foci by immunofluorescence at day 6.
(K) Quantification of (J). Mean of three independent experiments with SEM is shown. *p < 0.05.
(legend continued on next page)
1260 Cell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authors
the senescence status of human benign nevi and melanoma
specimens, and high RRM2 expression significantly correlates
with worse overall survival in patients with melanoma.
Finally, we wanted to determine whether melanoma cells
harboring activated oncogenes can be driven to undergo senes-
cence by knockdown of RRM2. To do this, UACC-62 human
melanoma cells were infected with two individual shRRM2s.
The knockdown efficacy of shRRM2s in UACC-62 cells was
confirmed by immunoblotting (Figure 7H). The growth of
UACC-62 cells was notably inhibited by knockdown of RRM2,
as determined by cell growth curves (Figure 7I) and colony
formation (Figure 7J). Interestingly, the DDR marker gH2AX
was upregulated by RRM2 knockdown (Figure 7H). To determine
whether these cells were undergoing senescence, SA-b-gal
activity was assessed. Indeed, UACC-62 cells infected with
shRRM2 had significantly increased SA-b-gal activity compared
to controls (Figures 7K and 7L). Similar results were also
obtained with another melanoma cell line, WM164 (Figures
S6L–S6P), suggesting that the observed effects are not cell
line specific. These results demonstrate that knockdown of
RRM2 in melanoma cells suppresses the growth of these cells
by triggering cellular senescence.DISCUSSION
In this study, we demonstrate that a decrease in dNTP levels
underlies the establishment and maintenance of the stable
OIS-associated cell growth arrest. Mechanistically, we discov-
ered that the decrease in dNTP levels is due to the transcrip-
tional repression of the RRM2 gene through recruitment of
E2F7 prior to the senescence-associated cell-cycle exit. This
correlates with aberrant DNA replication and coincides with
the DDR during OIS. Notably, RRM2 downregulation is both
necessary and sufficient for senescence, which correlates with
its effects on the changes in cellular dNTP levels. Significantly,
we demonstrated that suppression of nucleotide metabolism
through RRM2 repression is necessary for maintenance of the
stable OIS-associated cell growth arrest because established
senescent cells can reenter the cell cycle after expression of
ectopic RRM2. Underscoring the physiological relevance of
the current discovery, we showed that RRM2 repression posi-
tively correlates with the senescence status of melanocytes in
human benign nevi and melanoma specimens harboring onco-
genic BRAF or NRAS. Additionally, high RRM2 expression
correlates with poor overall survival in patients with melanoma
harboring oncogenic BRAF or NRAS. Knockdown of RRM2 in
human melanoma cells with activated oncogenes drives senes-
cence of these cells, supporting the hypothesis that RRM2
promotes melanoma by suppressing the senescence tumor
suppression mechanism.(L) Same as (A) but examined for p53, gH2AX, and b-actin expression by immun
(M) IMR90 cells were infected with RAS-encoding retrovirus. On day 6, establish
vector control. After an additional 14 days, the cells were stained for SA-b-gal ac
(N) Quantification of (M). Mean of three independent experiments with SEM is sh
(O) Same as (M) but examined for RAS, RRM2, p16, pS10H3, and b-actin expres
(P) Same as (M), but an equal number of cells were inoculated in 6-well plates, an
independent experiments with SEM is shown. *p < 0.05.
CWe show that addition of exogenous nucleosides in estab-
lished senescent cells is able to overcome the senescence-
associated cell growth arrest (Figure 2). In addition, knockdown
of RRM2 expression drives senescence and the associated cell
growth arrest (Figures 5 and S5). Conversely, ectopic RRM2 is
sufficient to overcome the stable senescence-associated cell
growth arrest (Figure 6). These observed effects correlate with
the changes in dNTP levels in these cells (Figures 5, 6, and
S5). Significantly, RRM2 repression, which drives the decrease
in dNTP levels, occurs prior to the senescence-associated
cell-cycle exit (Figures 4A and 4B), demonstrating that the
observed effects are not a consequence of senescence or its
associated cell growth arrest. These results support the premise
that the decrease in dNTP levels induced by RRM2 repression is
necessary and sufficient for establishing andmaintaining the sta-
ble senescence-associated cell growth arrest induced by acti-
vated oncogenes.
OIS is characterized by aberrant DNA replication during the
S phase of the cell cycle, which triggers the DDR (Bartkova
et al., 2006; Di Micco et al., 2006). Here, we show that dNTP
levels are decreased prior to the OIS-associated cell-cycle exit
(Figure 3A), and addition of exogenous nucleosides significantly
rescues the aberrant DNA replication and DDR during OIS
(Figures 1D, 1E, 3B, and 3C). These data indicate that there is
a correlation between the decrease in dNTP pools and aberrant
DNA replication and DDR during OIS. However, the effect of nu-
cleosides on OIS is not a consequence of DDR because senes-
cence induced by DNA-damaging agents such as doxorubicin
and etoposide is not affected by exogenous nucleosides (Fig-
ures S1B–S1I). This further supports the premise that the
decrease in dNTP levels is specifically linked to aberrant DNA
replication during OIS. Indeed, RRM2 knockdown decreases
dNTP levels and triggers aberrant DNA replication and the
DDR (Figures 5B–5D and S5C–S5E). Conversely, ectopic
RRM2 rescues the decrease in dNTP levels and suppresses
the aberrant DNA replication and DDR induced by activated on-
cogenes (Figures 6H–6K). Together, these data support a model
whereby oncogene-induced repression of RRM2 decreases the
dNTP levels, which triggers aberrant DNA replication and the
DDR and, ultimately, OIS-associated cell growth arrest. It is
possible that the DDR triggered by aberrant DNA replication is
irreparable in the context of oncogene activation because of
the lack of dNTPs due to RRM2 repression. This causes persis-
tent DDR observed in established senescent cells (Rodier et al.,
2009) and underlies the stable OIS-associated cell growth arrest.
One of the classical examples of OIS as a tumor suppression
mechanism is melanocytic nevi arising from oncogenic BRAF or
NRAS (Kuilman et al., 2010). The stable growth arrest observed
in these lesions is thought to prevent transformation of these
cells into malignant melanoma (Mooi and Peeper, 2006). Here,oblotting.
ed senescent cells were infected with a lentivirus encoding RRM2 or an empty
tivity.
own. *p < 0.001.
sion by immunoblotting.
d the number of cells was counted at the indicated time points. Mean of three
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Figure 7. RRM2 Is Repressed in Human
Benign Nevi, whereas Overexpressed in
Melanoma; Knockdown of RRM2 Drives
Senescence of Melanoma Cells
(A) Melanocytes were infected with a lentivirus
encoding control or BRAFV600E. At 21 days after
infection, cells were examined for BRAF, RRM2,
p16, p21, pS10H3, gH2AX, and b-actin expression
by immunoblotting.
(B) Same as (A) but examined for SA-b-gal
activity.
(C) Quantification of (B). Mean of two independent
experiments with SEM is shown. *p < 0.01.
(D) RRM2 and b-actin expression in two individ-
ual isolations of normal human melanocytes and
the indicated human melanoma cell lines by
immunoblotting is shown. Mutation status of
BRAF and NRAS of the selected cell lines is
indicated.
(E) Immunohistochemical staining of RRM2, p16,
and Ki67 in benign human nevus (N) and human
melanoma tissue specimens harboring oncogenic
BRAF or NRAS. Shown are examples of a benign
human nevus and a human melanoma tissue
harboring oncogenic BRAFV600E. S, stroma; E,
epidermal compartments.
(F) Quantification of RRM2 staining in (E).
Expression of RRM2 in benign human nevi (n = 5)
and melanoma tissue specimens (n = 7) was
quantified using the histological score. Mean of
three independent experiments with SEM is
shown.
(G) A high level of RRM2 expression correlates
with shorter overall survival in human patients with
melanoma harboring oncogenic BRAF or NRAS.
The univariate overall survival curve (Kaplan-Meier
method) for patients with melanoma (n = 50) with
high or low RRM2 expression is detailed in
Experimental Procedures.
(H) UACC-62 human melanoma cells were in-
fected with control or two individual shRRM2s
encoding lentivirus. RRM2, cyclin A, gH2AX, and
b-actin expression was determined by immuno-
blotting.
(I) Same as (H), but an equal number of cells were
seeded in 6-well plates, and the number of cells
was counted at the indicated time points. Mean of
three independent experiments with SEM is
shown. *p < 0.05 compared with controls.
(J) Same as (I), but after 2 additional weeks, the
plates were stained with 0.05% crystal violet in PBS to visualize colony formation. Shown are representative images of three independent experiments.
(K) Same as (H) but stained for SA-b-gal activity.
(L) Quantification of (K). Mean of three independent experiments with SEM is shown. *p < 0.05 compared with controls.
See also Figure S6 and Table S1.we found that RRM2 repression correlates with senescence
status in human melanocytic nevi and melanoma specimens
harboring oncogenic BRAF or NRAS (Figure 7). Interestingly,
as previously reported by Michaloglou et al. (2005), expression
of the senescence marker p16 in melanocytic nevi is heteroge-
neous with a proportion of negative expression cells (Fig-
ure 7E). In contrast, RRM2 repression occurs in nearly all
melanocytes within the benign nevi (Figures 7E and 7F). This
suggests that suppression of nucleotide metabolism plays a
broader role inmaintaining theOIS-associated stable cell growth1262 Cell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authorsarrest, such as the one observed in melanocytic nevi, compared
to p16. Together, these findings are consistent with the idea
that RRM2 repression is necessary for the stable cell growth
arrest observed in OIS-associated benign lesions such as mela-
nocytic nevi.
Cellular dNTP levels play a role in regulating cell proliferation
by controlling DNA synthesis (Reichard, 1988). Here, we show
that activation of oncogenes decreases dNTP levels in primary
human cells prior to OIS-associated cell growth arrest due to
oncogene-induced RRM2 downregulation (Figures 3 and 6H).
This suggests that RRM2 downregulation leads to an uncoordi-
nated cell proliferation and dNTP supply, which ultimately leads
to senescence and the associated cease of proliferation. Consis-
tently, changes in nucleotide metabolism have been implicated
in the early stages of cancer development. For example, the viral
oncogenic protein HPV16 E6/7 induces genomic instability by
suppressing dNTP synthesis (Bester et al., 2011). Furthermore,
we show that RRM2 repression correlates with senescence sta-
tus in human nevi or melanoma specimens harboring oncogenic
BRAF or NRAS (Figures 7 and S6). Consistently, knockdown of
RRM2 drives the senescence of melanoma cells harboring acti-
vated oncogenes (Figures 7H–7L and S6L–S6P). These data are
consistent with a model whereby RRM2 expression regulates
the OIS-associated cell growth arrest by acting as a key switch
for the coordinated cell proliferation and dNTP supply.
We show that RRM2 is downregulated at the transcriptional
level during OIS (Figures 4C and 4D). In addition, we show that
RRM2 transcriptional repression correlates with an enhanced
association with E2F7, a transcriptional repressor, with the pro-
moter of theRRM2 gene (Figure 4E). This correlates with a simul-
taneous decrease in binding of transcriptional activator E2F1 to
the RRM2 gene promoter. Indeed, E2F7 upregulation demon-
strated the same kinetics as RRM2 downregulation during OIS
(Figure 4F). Consistent with our observation, E2F7 has recently
been shown to be upregulated during the early stages of senes-
cence (Aksoy et al., 2012). In addition, RRM2 has also been
shown to be regulated by c-Myc (Liu et al., 2008), a key regulator
of the nucleotide biosynthetic pathway (Dang, 1999, 2011). Thus,
it is plausible that c-Myc may cooperate indirectly with E2F7 and
E2F1 in regulating RRM2 transcription prior to the senescence-
associated cell-cycle exit.
We found that RRM2 is significantly overexpressed in mela-
noma cells (Figures 7D–7F). Notably, supraphysiological levels
of RRM2 can lead to genomic instability, DNA damage, and
tumorigenesis by causing an imbalance in dNTP pools (D’Angio-
lella et al., 2012; Xu et al., 2008). Here, we show that supraphy-
siological levels of RRM2 observed in melanoma cells correlate
with loss of expression of markers of senescence in melanoma
specimens (Figure 7). In addition, we found that markers of the
DDR remain high in RAS-infected primary human fibroblasts ex-
pressing supraphysiological levels of RRM2 (Figures S6G and
S6H). These data support the notion that supraphysiological
levels of RRM2 suppress OIS and simultaneously promote
genomic instability by allowing error-prone replication due to
an imbalance in dNTP pools, which ultimately drives tumorigen-
esis. These data also demonstrate the important role of RRM2 in
cancer development by controlling dNTP pools. Indeed, RRM2
knockdown in human melanoma cells harboring oncogenic
BRAF suppressed the proliferation of these cells by triggering
senescence (Figures 7H–7L and S6L–S6P). The p53 and pRB
tumor suppressor pathways are key senescence effectors (Cam-
pisi and d’Adda di Fagagna, 2007; Courtois-Cox et al., 2008;
Kuilman et al., 2010). Notably, p53 is mutated in the WM164
cell line (Weiss et al., 1993). In addition, p16 is deleted in the
UACC-62 cell line (Ikediobi et al., 2006) and mutated in the
WM164 cell line (Ohta et al., 1994). However, knockdown of
RRM2 in these cells was able to induce senescence (Figures
7H–7L and S6L–S6P). Therefore, senescence induced byCRRM2 inhibition in melanoma cells is independent of both p53
and p16. This indicates that human cancer cells that lack func-
tional p53 and p16 retain the capacity to undergo senescence
through suppressing RRM2. These data suggest that inhibition
of the nucleotide biosynthetic pathway by suppressing RRM2
represents a bona fide target for driving cancer cells to undergo
senescence.
In summary, suppression of nucleotide metabolism via RRM2
repression underlies the establishment and maintenance of the
stable cell growth arrest, the hallmark that characterizes OIS
as an important tumor suppression mechanism. These data
place altered nucleotide metabolism at the heart of OIS regula-
tion and provide the molecular basis by which the stable OIS-
associated cell growth arrest is established and maintained.
EXPERIMENTAL PROCEDURES
Retrovirus and Lentivirus Infections
Retrovirus production and transduction were performed as described previ-
ously (Tu et al., 2011; Ye et al., 2007; Zhang et al., 2005) using Phoenix cells
to package the infection viruses (Dr. Gary Nolan, Stanford University). Lenti-
virus was packaged using the ViraPower Kit (Invitrogen, Carlsbad, CA, USA)
following the manufacturer’s instructions and as described previously (Li
et al., 2010; Tu et al., 2011; Ye et al., 2007). Cells infectedwith viruses encoding
the puromycin-resistance gene were selected in 3 mg/ml puromycin.
FACS for C12FDG Expression
Cells were incubated with 33 mM C12FDG (Invitrogen) for 1 hr as described
previously by Debacq-Chainiaux et al. (2009). After rinsing with PBS,
C12FDG-positive cells were sorted using a FACS ARIAII (BD Biosciences,
San Jose, CA, USA).
DNA-Combing Analysis
Cells were pulse labeled for 10 min with medium containing 2 mM of BrdU
(Sigma-Aldrich), washed twice with PBS, incubated in regular medium for
20 min, and then chased for 20 min with medium containing 2 mM iododeox-
yuridine (IdU; Sigma-Aldrich). Harvesting and spreading of DNA fibers were
performed as previously described by Merrick et al. (2004). The DNA fibers
were stained with antibodies to BrdU (Abcam) and IdU (Fitzgerald Industries,
Acton, MA, USA), and the staining was visualized using secondary antibodies
labeled with FITC and Cy3, respectively. DNA fibers were counterstained with
a primary antibody to ssDNA (Millipore) and were visualized with a secondary
antibody labeled with Alexa Fluor 350 (Invitrogen), allowing the exclusion of
any broken or tangled fibers. DNA replication forks were scored as
elongating, terminated, or newly fired, as previously described by Bartkova
et al. (2006).
Measurement of dNTP Concentrations in Cells
Briefly, 53 106 cells were harvested and resuspended in 80%methanol. Cells
were vortexed and stored at20C overnight. Next, cells were boiled for 3min
and centrifuged at 4C at 17,0003 g for 20 min. Supernatants were harvested
and dried using a vacuum centrifuge. Pellets were resuspended in nuclease-
free water and stored at 20C until use. dNTP concentration was measured
as previously described by Wilson et al. (2011).
ChIP Analysis
ChIP in control and RAS-infected IMR90 cells was performed at day 2 as
previously described (Zhang et al., 2007b) using antibodies against E2F1
(Santa Cruz Biotechnology), E2F7 (Santa Cruz Biotechnology), or an isotype-
matched IgG control. Immunoprecipitated DNA was analyzed using SYBR
Green qPCR Mastermix (SA Biosciences, Valencia, CA, USA) against the
human RRM2 gene promoter region containing the E2F1/E2F7 binding
site using the following primers: forward, 50-CTCCAGCTCCTGGCCTCAA-30,
and reverse, 50-RCCGCGTGGACTGTTAATGC-30.ell Reports 3, 1252–1265, April 25, 2013 ª2013 The Authors 1263
Immunofluorescence, BrdU Labeling, and SA-b-Gal Staining
Immunofluorescence staining and BrdU labeling were performed as described
previously using antibodies described above (Tu et al., 2011; Zhang et al.,
2005, 2007a, 2007b). SA-b-gal staining was performed as previously
described (Dimri et al., 1995). For quantification, a minimum of 200 cells
from each group was examined.
Please see the Extended Experimental Procedures for further details.
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